Stryker (SYK) to Release Earnings on Thursday

Stryker (NYSE:SYK) is anticipated to announce its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of $2.76 per share and revenue of $5.68 billion for the quarter. Stryker has set its FY 2025 guidance at 13.450-13.700 EPS.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the business earned $3.46 EPS. On average, analysts expect Stryker to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Stryker Stock Up 2.6 %

Stryker stock opened at $357.33 on Thursday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $136.39 billion, a P/E ratio of 46.05, a P/E/G ratio of 2.93 and a beta of 0.93. The firm has a 50 day moving average price of $368.69 and a 200-day moving average price of $372.95. Stryker has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. BTIG Research set a $403.00 price target on Stryker and gave the stock a “buy” rating in a research note on Monday, April 14th. Canaccord Genuity Group increased their target price on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Barclays raised their price objective on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $423.53.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Stryker

A hedge fund recently raised its stake in Stryker stock. Brighton Jones LLC grew its position in shares of Stryker Co. (NYSE:SYK) by 15.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,564 shares of the medical technology company’s stock after acquiring an additional 609 shares during the period. Brighton Jones LLC’s holdings in Stryker were worth $1,643,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.